

# CBB1007

Catalog No: tcsc1737



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1379573-92-8

**Formula:**

$C_{27}H_{34}N_8O_4$

**Pathway:**

Epigenetics

**Target:**

Histone Demethylase

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

534.61

## Product Description


CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1

selective inhibitor ( $IC_{50} = 5.27 \mu M$  for hLSD1).

$IC_{50}$  Value: 5.27  $\mu M$

Target: hLSD1

CBB1007 efficiently can block LSD1-mediated demethylation of H3K4Me2 and H3K4Me ( $IC_{50} \leq 5 \mu M$ ) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents ( $IC_{50} \leq 5 \mu M$ ), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells ( $IC_{50} \leq 3.74 \mu M$ ). CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells ( $IC_{50} \geq 100 \mu M$ ).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!